Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of perampanel (E2007) in refractory partial-onset seizures
jRCT2080221861Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2012
- Modality
- Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of perampanel in epilepsy (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Efficacy of perampanel 8 and 12 mg/day on seizure control. Started Jul 2012; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on jRCT2080221861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221861.